Discriminating Prion Diseases from Alzheimer’s Disease Using Plasma Biomarkers: The Crucial Role of NfL/p-tau217 Ratio
Plasma phosphorylated tau biomarkers overlap in Alzheimer’s and prion diseases, risking diagnostic confusion. The NfL/p-tau217 ratio emerges as an accurate plasma biomarker to distinguish prion diseases from Alzheimer’s, improving diagnostic precision and guiding appropriate clinical management.